Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zi-Hao Qi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110566938. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: 3 papers · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. [Corrigendum] RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2025.5822↗
  2. Angiogenesis in pancreatic cancer: current research status and clinical implications. Co-author DOI 10.1007/s10456-018-9645-2↗
  3. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6941-4↗
  4. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Co-author DOI 10.2174/0929867325666180413101722↗
  5. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. Co-author DOI 10.1016/j.hbpd.2018.03.007↗
  6. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  7. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2018.4269↗
  8. The Significance of Liquid Biopsy in Pancreatic Cancer. Co-author DOI 10.7150/jca.24591↗
  9. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.08.005↗
  10. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… Co-author DOI 10.1038/srep19222↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaxiang Xu · 10 shared papers, 2016–2026 · strength 0.94
  2. Chuntao Wu · 10 shared papers, 2016–2026 · strength 0.94
  3. Xianjun Yu · 10 shared papers, 2016–2026 · strength 0.94
  4. Liang Liu · 8 shared papers, 2016–2026 · strength 0.80
  5. He-Li Gao · 7 shared papers, 2018–2026 · strength 0.74
  6. Shi-Rong Zhang · 7 shared papers, 2018–2026 · strength 0.74
  7. Jin-Zhi Xu · 7 shared papers, 2018–2026 · strength 0.74
  8. Wen-Quan Wang · 8 shared papers, 2016–2019 · strength 0.58
  9. Wenquan Wang · 2 shared papers, 2019–2026 · strength 0.35
  10. Wei Jin · 3 shared papers, 2018–2019 · strength 0.23
  11. Quanxing Ni · 3 shared papers, 2018–2019 · strength 0.23
  12. Jin Xu · 3 shared papers, 2016–2018 · strength 0.18
  13. Jiang Long · 3 shared papers, 2016–2018 · strength 0.18
  14. Chen Liu · 3 shared papers, 2016–2018 · strength 0.18
  15. Shuo Li · 2 shared papers, 2018–2019 · strength 0.15
  16. Jin-Feng Xiang · 2 shared papers, 2016–2017 · strength 0.12
  17. Heli Gao · 1 shared paper, 2019 · strength 0.08
  18. Hao Li · 1 shared paper, 2019 · strength 0.08
  19. Shirong Zhang · 1 shared paper, 2019 · strength 0.08
  20. Wei Jin · 1 shared paper, 2019 · strength 0.08
  21. Shuo Li · 1 shared paper, 2019 · strength 0.08
  22. Liang Liu · 1 shared paper, 2018 · strength 0.07
  23. Jingxuan Yang · 1 shared paper, 2016 · strength 0.05
  24. Min Li · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.